O
Ophelia
Biotech & Life Sciences · Philadelphia, United States · Founded 1994
Medication and support for opioid withdrawal, in the privacy of home MoreLess
Ophelia is a healthcare startup focused on providing medication-assisted treatment (MAT) for individuals struggling with opioid dependence. The company operates in the healthcare sector, specifically targeting patients who are experiencing cravings or withdrawal symptoms related to opioid use. Ophelia's business model revolves around offering scientifically-backed treatments that replace traditional rehab methods with a more modern, private, and convenient approach. The company makes money by providing these medical services directly to patients, leveraging a team of doctors, scientists, and tech experts to deliver high-quality care. Ophelia's mission is to eliminate the stigma associated with drug rehab by offering a discreet and effective alternative that empowers patients to make their own choices. The company serves a diverse clientele, primarily focusing on individuals under the age of 50, who are at the highest risk of opioid overdose. By combining medical expertise with a patient-centric approach, Ophelia aims to revolutionize the way opioid dependence is treated in the United States.
Keywords: opioid dependence, medication-assisted treatment, healthcare startup, opioid cravings, withdrawal symptoms, patient-centric, privacy, convenience, scientific treatment, modern rehab.
Company overview
Ophelia company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 1994
- Headquarters
- Philadelphia, United States
- Employees
- 374
- Open positions
- None listed
- Dealroom signal
- 86.5
Valuation & funding
Ophelia funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2021 | $50M | $200M | Interplay · Refactor Capital · General Catalyst · Menlo Ventures | ↗ |
| SERIES AOther financing | Apr 2021 | $15M | $60M | Refactor Capital · Bloom Institute of Technology · Menlo Ventures · General Catalyst | — |
| SEEDOther financing | Jul 2020 | $125K | $500K | Y Combinator | — |
| SEEDOther financing | Mar 2020 | $2.7M | $11M | General Catalyst · Y Combinator · Refactor Capital | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $22M | 0% | 374 |
| 2025 | $22M | 0% | 333 |
| 2024 | $22M | 0% | 294 |
| 2023 | $22M | +52.1% | 199 |
| 2022 | $14M | +491.7% | 217 |
| 2021 | $2.4M | — | — |
Growth signals
Ophelia website traffic
Latest recorded traffic for Ophelia is 580K monthly website visits, down 29.3% over the last three months. Ophelia's team grew 12.3% over the past year.
Comparisons
Ophelia compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Ophelia's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Ophelia has talent and traffic
team presence
In the news
Latest news about Ophelia
Recent press, funding announcements, and product moves mentioning Ophelia — open to read from the original sources.
Market sentiment
What the market is saying about Ophelia
An AI-synthesized read of the highest-engagement posts about Ophelia on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ophelia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.